---
run_id: halo-evidence-vs-diagnosis-validation-v7-vanilla-04
created: 2026-05-23
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v7
benchmark_version: halo-evidence-vs-diagnosis-validation-v7-v1
model_condition: vanilla
run_number: 4
model_name: gemma4:31b
model_id: gemma4:31b
model_snapshot: Ollama model ID 6316f0629137
runtime: Ollama local HTTP server; version 0.24.0
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 32768
seed: 401
prompt_source: condition packet (vanilla) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 5a42e17859b4a23ae36d2682474f8d0369ffc492c200375fd79a14bf3b322262
source_packet: the frozen Advisor prompt alone, with no added material - see run-packet.md
source_packet_sha256: 5a42e17859b4a23ae36d2682474f8d0369ffc492c200375fd79a14bf3b322262
condition_packet_sha256: 5a42e17859b4a23ae36d2682474f8d0369ffc492c200375fd79a14bf3b322262
output_file: model-outputs/vanilla-04.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - vanilla (run 04)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v7-v1`, condition `vanilla`, run 4 of 8. Real local-model run: `gemma4:31b` via Ollama, seed 401, on the frozen condition packet.

## Output

**Recommendation: Run the targeted evidence pass.**

You should advise the CEO to pause the aggressive rollout and the "upbeat" narrative to conduct a rigorous validation of Review Assist. The current growth is a "mirage" created by financial engineering (discounts) and sales signaling (telling customers it's the top priority), rather than genuine product-market fit.

**Why:**
Your data shows a dangerous divergence between *Buyer* sentiment and *User* behavior. The revenue bump is artificial—72% of the expansion is tied to temporary discounts—and the usage is skewed. When only 31% of front-line reviewers return after the first week, you don't have a "market wedge"; you have a "leaky bucket."

Furthermore, the reclassification of product issues as "training questions" and the abandonment of the tool in regulated insurance queues suggest a fundamental product failure: the "Black Box" problem. In compliance, a tool that provides an answer without a defensible audit trail is a liability, not a feature. Scaling now would mean hiring implementation teams to deploy a product that users are actively avoiding, which will lead to a catastrophic churn event once the six-month discounts expire and the procurement windows close.

**The strongest reason against this:**
**Political and Momentum Risk.** The CEO and Sales leadership are currently experiencing a "win." They have a board packet that looks great and a sales team that feels emboldened. Recommending a "pause" to gather evidence will be framed as "analysis paralysis" or "lack of urgency." You are essentially asking the CEO to tell the board that the upbeat story is premature, which risks the budget lock and may be perceived as a lack of confidence in the product team's ability to execute.

**The observable evidence that would change my mind:**
I would pivot to the "Scale Broadly" option only if you saw a significant, organic spike in **front-line reviewer retention (the 31% figure)** that was uncorrelated with the "strategic-feature pitch." If users who were *not* told the feature was a priority began returning at rates of 60% or higher, it would prove the product's intrinsic value outweighs the current "explainability" hurdles and sales pressure. Until the user-level data mirrors the revenue-level data, scaling is just accelerating a crash.
